Physician profile
Swathi Paleti
NPI 1548675143
$3,718.65
in general payments reported to CMS, 2019-2025
17 companies · $903 in 2025
The $903 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $496 · 2020: $67.16 · 2021: $53.99 · 2022: $139 · 2023: $990 · 2024: $1,070 · 2025: $903.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,962.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,962.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,638.92 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $722.71 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $235.81 | 2020-2025 | Xifaxan |
| Janssen Biotech, INC. | $216.18 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Exelixis INC. | $191.94 | 2019-2025 | Cabometyx |
| Pfizer INC. | $142.53 | 2023-2025 | |
| Ardelyx, INC. | $132.51 | 2024-2025 | Ibsrela |
| Gilead Sciences, INC. | $126.40 | 2019-2025 | |
| Boston Scientific Corporation | $89.06 | 2019-2023 | |
| Celgene Corporation | $63.52 | 2022-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $41.59 | 2019-2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $37.01 | 2024 | Voquezna |
| Enterra Medical, INC. | $32.50 | 2025 | |
| Mallinckrodt Hospital Products INC. | $18.37 | 2024 | Terlivaz |
| Ferring Pharmaceuticals INC. | $14.96 | 2023 | Rebyota |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $14.64 | 2025 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swathi Paleti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.